Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Do Platform Disease-Modifying Therapies Differ in Multiple Sclerosis Progression?
1+ hour, 1+ min ago (389+ words) Do Platform DMTs Differ in Multiple Sclerosis Progression? Medscape Do Platform Disease-Modifying Therapies Differ in Multiple Sclerosis Progression? Among patients with relapsing-remitting multiple sclerosis (RRMS), oral and injectable platform disease-modifying therapies (DMTs) showed no significant differences in the risk for…...
Broward Health Medical Center Introduces Bispecific T-Cell Engager Therapy for Cancer Patients
1+ hour, 18+ min ago (231+ words) Posted by cfelixcpa | Oct 14, 2026 | SF STAT! | 0 | OCTOBER 13, 2026 – Broward Health Medical Center has introduced bispecific T-cell engager (BiTE) therapy, an innovative immunotherapy that harnesses the body’s immune system to target and destroy cancer cells. The FDA-approved therapy is used to treat…...
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
2+ hour, 16+ min ago (866+ words) The partners will collect real-world outcomes and conduct formal studies; patients can go home the same day after the ultrasound-guided procedure. - Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center The center is already treating patients, while…...
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
2+ hour, 46+ min ago (447+ words) The designation brings development incentives, with 10 years of European market exclusivity conditional on marketing approval. Quoin Pharmaceuticals (NASDAQ: QNRX) has received European Medicines Agency orphan drug designation for QRX003 to treat Peeling Skin Syndrome. The designation provides scientific advice on study…...
Science Corp Implants Vision Chip in First Stargardt Patient
7+ hour, 41+ min ago (336+ words) Science Corporation says it has placed its PRIMA retinal implant in a patient with Stargardt disease for the first time, extending a device that is already sold in Europe for a different eye condition. The announcement came from CEO Max…...
ACS Fellow Helps Advance Bionic Arm Technology
14+ hour, 16+ min ago (397+ words) Jason Ko, MD, MBA, FACS A Chicago-area patient has reached a surgical milestone toward receiving a bionic arm connected directly to bone, nerves, and muscles. The investigational approach aims to combine stable skeletal attachment with intuitive movement control and sensory…...
Amphista doses first patient in Phase I BRD9 degrader trial for AML
22+ hour, 6+ min ago (276+ words) AllSci UK-based Amphista Therapeutics has dosed the first patient in a Phase I trial of AMX-883, an oral DCAF16-mediated BRD9 degrader being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The news marks the company's first asset to…...
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
23+ hour, 43+ min ago (150+ words) PharmaDispatch Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy VVMF chief executive Stephen Thompson said, "We are pleased to be working with Peter Mac to evaluate the manufacturability of this AAV-based candidate and generate the…...
How Disease Burden Shapes First-Line RCC Treatment Selection
12+ hour, 30+ min ago (359+ words) In a virtual Case-Based Roundtable event, Neeraj Agarwal, MD, FASCO, medical oncologist and co-director of the Prostate Cancer Program at Dana-Farber Cancer Institute, moderated a discussion with oncologists in California on how disease burden, symptoms, and treatment goals inform first-line…...
Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026
19+ hour, 37+ min ago (565+ words) BioSpace Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026 - FTB-918 is a first-in-class, dual-targeting antibody fusion engineered to simultaneously deplete pathogenic T cells and neutralize IL-17A, addressing both a cellular driver and a…...